No Data
Legend Biotech Corporation (NASDAQ:LEGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Will Genscript Cash Out of Legend Biotech in the Face of Fat Profit Temptation?
Is Legend Biotech Corporation (LEGN) a Good Growth Stock to Buy?
Genscript Biotech's US-Listed Unit Forecasts Up to $110 Million in January-June Loss
Sector Update: Health Care Stocks Higher Late Afternoon
Legend biotech (LEGN.US) is expected to have a net loss of up to 0.11 billion US dollars in the first half of the year after adjustment.
Legend biotech (LEGN.US) is expected to have a net loss of approximately $94.7 million to $0.1097 billion in the first half of 2024 after adjustments.